Loading clinical trials...
Loading clinical trials...
Ridge Augmentation Treatment Using OSSIX® BREEZE vs Jason® Membrane in Simultaneous Implantations. A Prospective, Randomized Controlled Trial.
This is a prospective randomized controlled parallel trial. The aim of this study is to evaluate bone formation and soft tissue healing after 4 and 8 months in patients with ridge deficiencies in simultaneous implantation approach. The trial will compare a (sugar cross linked) - SCL pericardium membrane OSSIX® Breeze vs native pericardium membrane (Jason®).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Hadassah Medical Center
Jerusalem, Israel
Rabin Medical Center
Petah Tikva, Israel
University of Birmingham
Birmingham, United Kingdom
Start Date
December 1, 2022
Primary Completion Date
June 1, 2026
Completion Date
July 1, 2026
Last Updated
October 16, 2024
65
ESTIMATED participants
OSSIX Breeze
DEVICE
Jason membrane
DEVICE
Lead Sponsor
Datum Dental LTD
NCT07162727
NCT06388837
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06177899